Clinical Trials Browser

Phase 1/2 × Carcinoma, Merkel Cell × 30 days × Clear all

Lymphoma, Neoplasms, Carcinoma, Merkel Cell

NCT07472322 2026-05-29

ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

Phase 1/2 Not yet recruiting

31 enrolled

Dermatologic

Carcinoma, Merkel Cell

NCT06814496 2026-05-20

RABBIT

Phase 1/2 Recruiting

30 enrolled

CNSDermatologicGenitourinaryGynecologicThoracic

Sinonasal undifferentiated carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Glioblastoma, Melanoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory

NCT05267626 2026-05-18

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Phase 1/2 Recruiting

159 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Diabetes Mellitus, Insulin-Dependent, 10, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Carcinoma, Merkel Cell

Clinical Trials

MK-3475-G21

ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

RABBIT

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer